Products & Services · Revenue
Royalty — Revenue
Pfizer Royalty — Revenue increased by 28.6% to $396.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase suggests successful monetization of intellectual property and strong patent portfolio value, while a decrease may indicate patent expirations or reduced licensing activity.
Detailed definition
This metric represents the income generated from licensing intellectual property, patents, or proprietary technologies t...
Peer comparison
Comparable to licensing and royalty income reported by other large-cap pharmaceutical and biotechnology firms that leverage their R&D output through external partnerships.
Metric ID:
pfe_segment_royalty_revenuesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $308.00M | $396.00M |
| QoQ Change | — | +28.6% |
| YoY Change | — | +28.6% |
Range$308.00M – $396.00M
Avg YoY Growth+28.6%
Median YoY Growth+28.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's royalty — revenue?
- Pfizer (PFE) reported royalty — revenue of $396.00M in Q1 2026.
- What does royalty — revenue mean?
- Revenue earned from licensing the company's patents and intellectual property to other organizations.